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Abstract
Background: A wide variety of hemostats are available as adjunctive measures to improve hemostasis during surgical
procedures if residual bleeding persists despite correct application of conventional methods for hemorrhage control.
Some are considered active agents, since they contain fibrinogen and thrombin and actively participate at the end of
the coagulation cascade to form a fibrin clot, whereas others to be effective require an intact coagulation system. The
aim of this study is to provide an evidence-based approach to correctly select the available agents to help physicians to
use the most appropriate hemostat according to the clinical setting, surgical problem and patient’s coagulation status.
Methods: The literature from 2000 to 2016 was systematically screened according to PRISMA [Preferred Reporting Items
for Systematic Reviews and Meta-Analyses] protocol. Sixty-six articles were reviewed by a panel of experts to assign
grade of recommendation (GoR) and level of evidence (LoE) using the GRADE [Grading of Recommendations
Assessment, Development and Evaluation] system, and a national meeting was held.
Results: Fibrin adhesives, in liquid form (fibrin glues) or with stiff collagen fleece (fibrin patch) are effective in the
presence of spontaneous or drug-induced coagulation disorders. Mechanical hemostats should be preferred in
patients who have an intact coagulation system. Sealants are effective, irrespective of patient’s coagulation status,
to improve control of residual oozing. Hemostatic dressings represent a valuable option in case of external hemorrhage
at junctional sites or when tourniquets are impractical or ineffective.
Conclusions: Local hemostatic agents are dissimilar products with different indications. A knowledge of the properties
of each single agent should be in the armamentarium of acute care surgeons in order to select the appropriate product
in different clinical conditions.
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Background
A wide variety of hemostats are available as adjunctive
measures to improve hemostasis during surgical proce-
dures if residual bleeding persists despite correct appli-
cation of conventional methods for hemorrhage control.
Some are considered active agents, since containing
fibrinogen and thrombin and actively participating at
the end of the coagulation cascade to form a fibrin
clot [1–4]. These agents can be used effectively in pa-
tients with spontaneous or drug-induced coagulation
disorders. They are available in liquid flowable form
(fibrin glues) [1–9] or in association with stiff colla-
gen fleece (fibrin patch) [10–14]. These agents are
known as adhesive hemostats because of their
hemostatic and tissue sealing action [15–33].
Others, including porcine gelatin [34], oxidized cellu-
lose [35, 36], bovine collagen [37], and plant-derived
polysaccharides spheres [38, 39], are known as mechan-
ical hemostats, by providing platelet activation and ag-
gregation and forming a matrix at the site of bleeding,
which allows clotting to occur. Since they are not bio-
logically active, relying on patient’s own fibrin produc-
tion to achieve hemostasis, these agents are considered
passive hemostats and are only appropriate for patients
who have an intact coagulation system.
Sealants are low viscosity liquids that polymerize
forming a solid film that connects a-traumatically the
tissue surfaces [40–53]. This property makes these
agents effective both as sealants and as hemostats. They
can be divided in synthetic (cyanoacrylate and polyethyl-
ene glycol-PEG sealants) [42–51] and semisynthetic
(glutaraldheide albumin-derived sealants) [52, 53].
Hemostatic dressings represent a valuable option to
achieve hemostasis in the case of external hemorrhage at
junctional sites (axilla, groin), when the use of a tourni-
quet is ineffective or impractical. [54–64] They are clas-
sified as either factor concentrators (zeolite) [57, 58],
procoagulants (kaolin) [59], and mucoadhesives (chitin)
[60, 61]. They are available as granules/powders or ban-
dages [62] and are indicated for external use only.
The aim of this study is to provide an evidence-based
approach to correctly select the available agents, in order
to help physicians to use the most appropriate hemostat
in accordance with clinical setting, surgical problem and
patient’s coagulation status.
Methods
The Organizing Committee (O.C., S.C.) was established
to plan a National Meeting on the use of topical hemo-
stats in emergency surgery and trauma. The meeting
was conducted according to “The Methodological
Manual-How to Organize a Consensus Conference”, edi-
ted by the Higher Health Institute [65]. The meeting
was powered by the Italian Society of Emergency
Surgery and Trauma (SICUT) and endorsed by the
World Society of Emergency Surgery (WSES) and its
Italian Chapter (WSES.it). The representatives of the ex-
ecutive board of both societies were asked to participate.
A representative of each of the following companies
(ASSUT, Baxter, B-Braun, Takeda, Johnson &Johnson,
Medtronic, Medica, Valeggia, Medical, SVAS) attended
the meeting as auditors. The organizing committee se-
lected a scientific board (SB, 4 members) and a national
panel of experts (NPE, 5 members). The organizing
committee and SB selected the following main topics:
1. Adhesives
– Liquid fibrin adhesives
– Fibrin patch
2. Mechanical Hemostats
3. Sealants
4. Hemostatic Dressings (mineral and polysaccharides)
Each panelist was asked to answer the following key
questions and specific sub-questions pertaining to the
assigned topic:
1. Is the hemostat effective in the presence of
coagulation disorders?
2. Which type of hemorrhage (i.e. oozing, spurting,
mild, moderate) is best managed by the agent?
3. Is the agent effective to control fluid leakages
(biliary, pancreatic, urinary)?
4. Is the agent effective to control air leak?
5. Is the agent effective to protect vascular
anastomosis?
6. Is the agent effective to protect intestinal
anastomosis?
7. Which are the possible cautions against use of the
single agent?
A systematic review of the literature from 2000 to
2016 was undertaken by a medical reference librarian
in May 2016. An investigator (S.C.) created a prelim-
inary search strategy by selecting the following key
words: emergency surgery, trauma, hemorrhage,
hemostasis, hemostatic agents, biliary fistula, urinary
fistula, pancreatic fistula, anastomosis, air leak.
Searches were conducted incorporating novel terms
when relevant citations were found using the follow-
ing database: MEDLINE, PubMed, EMBASE, Scopus,
and Cochrane Database of Systematic Reviews. The
investigator (S.C.) screened titles and abstracts select-
ing studies according to PRISMA statements [66].
The following types of articles were included: (I)
prospective randomized controlled trials; (II) observa-
tional studies in which data were collected prospect-
ively; (III) retrospective analyses based on clearly
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reliable data; (IV) systematic reviews of literature; (V)
meta-analyses; and (VI) relevant case series: all arti-
cles eligible for evaluation were divided according to
the selected topics and sent for further evaluation to
the five national experts. They were asked to assign
levels of evidence (LoE) and grades of recommenda-
tions (GoR) based on the Grading of Recommenda-
tions, Assessment, Development and Evaluation
(GRADE) hierarchy criteria (Table 1) [67].
On May 15, 2017, a meeting was held involving the or-
ganizing committee, NPE, SB, and the representatives of
the scientific societies to discuss topics and define state-
ments to be presented during the 45th SICUT Congress,
held in Naples in October 2017. For each topic, a 35 min--
session was held with a presentation of hemostatic agent
characteristics, a literature review by a member of the
NPE, and a discussion with the representatives of the
Societies. It was all recorded for later analysis and subse-
quent manuscript preparation.
Results
The database searches identified 2150 citations (Fig. 1)
By removing duplicates, titles not related to the topic,
case reports, articles on non-trauma patients, articles on
pediatric trauma, articles on penetrating trauma, and ar-
ticles where a full text was unavailable, 2000 citations
were excluded. Of the remaining 150 citations, 84 were
excluded due to overlapping data or because they were
letters to the editor. The resulting 66 papers were
divided according to each topic: 33 for topic 1, 9 for
topic 2, 11 for topic 3, 13 for topic 4.
General considerations
Hemostats, irrespective of their nature, are not intended
as a substitute for a sound surgical technique and proper
application of ligatures or other conventional procedures
for hemostasis (1 A).
Scientific foundation
Surgical bleeding can be associated with an increased
risk of mortality and morbidity across all surgical
areas. In particular, bleeding complications arise in
nearly 30% of surgical procedures [2]. Moreover,
excessive bleeding often leads to increased
mortality-morbidity, longer hospital stays, and in-
creased healthcare costs. Hemostasis can be achieved
with conventional techniques such as manual pressure
and ligature; however, these can be ineffective in con-
trolling bleeding from complex injuries and in less
accessible areas. Energy-based methods, such as elec-
trocauterization or laser cauterization can also be
used; however, they create charred areas and necrotic
tissue, which increase the likelihood of infection.
Topical hemostats encompass a wide variety of
products which may help bleeding control, mostly in
challenging surgical settings or if patients are affected
by congenital or acquired coagulation disorders. Each
category of topical hemostat presents its own
Table 1 Grading of Recommendation from Guyatt et al. [67] (GRADE)
1A. Strong
recommendation,
high-quality evidence
Benefits clearly outweigh risks
and burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from observational
studies
Strong recommendation, applies to
most patients in most circumstances
without reservation
1B. Strong
recommendation,
moderate-quality
evidence
Benefits clearly outweigh risk and
burdens, or vice versa
RCTs with important limitations (inconsistent
results, methodological flaws, indirect analyses
or imprecise conclusions) or exceptionally
strong evidence from observational studies
Strong recommendation, applies to
most patients in most circumstances
without reservation
1C. Strong
recommendation,
low-quality or
very low-quality
evidence
Benefits clearly outweigh risk
and burdens, and vice versa
Observational studies or case series Strong recommendation but subject
to change when higher-quality
evidence becomes available
2A. Weak
recommendation,
moderate-quality
evidence
Benefits closely balanced with
risks and burdens
RCTs without important limitations or
overwhelming evidence from observational
studies
Weak recommendation, best action
may differ depending on the patient,
treatment circumstances, or social
values
2B. Weak
recommendation,
moderate-quality
evidence
Benefits closely balanced with
risks and burdens
RCTs with important limitations (inconsistent
results, methodological flaws, indirect analyses
or imprecise conclusions) or exceptionally
strong evidence from observational studies
Weak recommendation, best action
may differ depending on the patient,
treatment circumstances, or social
values
2C. Weak
recommendation,
low-quality or
very low-quality
evidence
Uncertainty in the estimates of
benefits, risks, and burdens; benefits,
risks, and burdens may be closely
balanced
Observational studies or case series Very weak recommendation, alternative
treatments may be equally reasonable
and merit consideration
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properties, which makes it eligible for use in different
circumstances.
Notwithstanding the contribution of these agents, irre-
spective of their nature, composition and mechanism of
action, they should not be intended as a substitute for a
sound surgical technique.
The classification of different agents, their mechanism
of action, advantages and caution against use are
depicted in Table 2.
Adhesives
Adhesives are active agents which participate at the
final step of coagulation cascade to form a fibrin clot.
They are constituted by two components: human
purified fibrinogen and/or thrombin. The two compo-
nents usually contain added plasmatic proteins such
as factor XIII, fibronectin, and an anti-fibrinolytic
agent like aprotinin or tranexamic acid [7]. Nowadays,
aprotinin-free and tranexamic acid-free formulations
are available [3, 5] reducing the risk of side effects,
such as aprotinin-associated hypersensitivity reactions,
and tranexamic acid-associated neurotoxicity [3, 5,
20–23]. Several adhesives are available as liquid for-
mulations (Evicel®, Crosseal™, Quixil®, Floseal®, Surgi-
flo®, Tisseel®, Beriplast P®) or as medicated sponge/
patch (Tachosil®, Evarrest®). Once applied irrespective
of their formulation, their mechanism of action is the
same: thrombin cleaves the fibrinogen into fibrin
monomers to form a soluble matrix. Thrombin also
activates factor XIII to factor XIIIa, which covalently
crosslinks the soluble fibrin matrix to form a stable
clot. Both these steps require the presence of calcium
ions [1]. Adhesives do not induce either inflammation
response or tissue necrosis, and they are metabolized
by fibrinolysis and phagocytosis in the same way as
endogenous fibrin [1].
Liquid fibrin adhesives
1. Liquid fibrin adhesives can be used as an adjunctive
measure, after sound surgical hemostasis, to improve
residual mild or moderate bleeding (oozing and/or
spurting) (1B)
2. Liquid fibrin adhesives are effective also in cases of
coagulation disorder, however, because they are
expensive, their use should be preferred in those
patients with spontaneous or drug-related coagula-
tion disorders (1A)
3. Fluid fibrin adhesives are more effective to control
residual bleeding on huge and regular raw surfaces
(2C)
4. Foam fibrin adhesives are more effective to control
residual bleeding in irregular and deep raw surfaces
(2C)
5. Intravascular administration of liquid fibrin
adhesives must be avoided because the
thromboembolic risk is high (1 B)
6. Liquid fibrin adhesives are effective to control
residual bleeding on vascular anastomosis (1B)
7. Liquid fibrin adhesives containing tranexamic acid
must not be used if cerebrospinal fluid leakage or
dura mater tear are present, because of
neurotoxicity (1A)
8. Liquid fibrin adhesives are not effective in preventing
pancreatic, biliary, urinary, intestinal and air
leakages. Therefore, their routine use should not be
recommended (1B)
Scientific foundation
Although all liquid fibrin products contain fibrinogen
and/or thrombin, they differ from each other in several
respects, including composition and ease of use. One as-
pect is the speed of hemostasis, the characteristics of
Fig. 1 Bibliography search (PRISMA). This figure represents the methodology applied to screen abstract and papers, in order to identify relevant
papers to be used for manuscript preparation
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fibrin clot and the agent’s safety profile [1]. In particular,
a higher fibrinogen concentration tends to produce a
stronger, but slow forming clot, whereas higher throm-
bin concentrations result in rapid clot formation, but the
clot formed is not as strong.
Liquid fibrin adhesives are applied by means of a sin-
gle or double syringe system, which allows the applica-
tion through a blunt needle or spray tips. The spray tip
is particularly useful when the surgical setting requires a
large and uniform deposition of the product [1, 7]. Fluid
formulations are more effective if the raw surface is huge
and regular, whilst foam products seem to be preferred
if the bleeding surface is deep in the parenchyma and ir-
regular, because of better adherence to tissue of this
physical form [2], due to its tendency to expand.
Safety concerns include the fact that any product con-
taining thrombin should never be injected intravascu-
larly because this administration may be associated with
thrombosis, hypotension and death. Moreover, a risk of
air embolism is present with the use of gas driven
sprayers, particularly when the adhesive is applied at
higher pressures (> 20–25 psi) against manufacturer rec-
ommendations, or at shorter distances (< 10–15 cm) [7].
Liquid fibrin products, when conventional hemostatic
methods are ineffective or impractical, can be used to
control residual mild or moderate bleeding in several
surgical settings.
Craig and coworkers [5], in a randomized, multicenter,
active-controlled study evaluated the efficacy and the ef-
fectiveness of liquid fibrin adhesive, in comparison to
mechanical hemostats, to control mild to moderate bleed-
ing on 124 patients undergoing retroperitoneal and intra-
peritoneal procedures at 10 min after randomization.
Overall, a higher percentage of patients who received liquid
fibrin adhesive achieved hemostasis within 10 min com-
pared with those who received the mechanical hemostat
(RR 1.16, 95% CI, 1.02–1.35; p < .05). In particular, 100% of
patients managed with liquid fibrin adhesive for mild
bleeding achieved hemostasis within 10 min, versus 88.9%
of subjects receiving mechanical hemostat (p < .002).
Moreover, a higher percentage of patients who received
liquid fibrin adhesive to treat moderate bleeding achieved
hemostasis within 10 min, compared with those who
received mechanical hemostat (87% vs 73.1%, respectively,
p < .05).
Mimicking the end steps of the coagulation cascade,
supplying exogenous fibrinogen and/or thrombin, liquid
fibrin adhesives are particularly effective in achieving
hemostasis in congenital or acquired bleeding disorders
(e.g. hemophilia patients, patients receiving antiplatelet
or anticoagulation therapies undergoing urgent surgical
procedure) [1, 3, 9].
There is evidence that bleeding control and postopera-
tive blood transfusion requirements in patients with
hemophilia undergoing major orthopedic procedures,
such as total knee and total hip replacement, improve if
liquid fibrin adhesives are used [1].
Liquid fibrin adhesives seem to be effective in reducing
the time to achieve hemostasis in post-cardiopulmonary
bypass coagulopathy patients, in decreasing the amount
of intraoperative blood loss and of blood product re-
quirements [1, 3].
Notwithstanding these advantages, the cost of the
fibrin sealants, ranging from $50 to $600 [7], is not neg-
ligible, and may also be important in determining thera-
peutic choices.
One cost-effectiveness analysis [1] conducted in the
UK on patients undergoing total knee replacement esti-
mated that use of a 5 mL dose of Quixil® in addition to
conventional hemostatic methods was cost saving com-
pared to conventional methods alone, and reduced the
expected cost by £296 per procedure. However, use of a
10 mL dose increased the expected cost by £94 per pro-
cedure. For this reason, the use of liquid fibrin adhesive
should be titrated on selected cases.
Several studies are available [3, 8, 9] pertaining to the
effectiveness of liquid fibrin adhesives in controlling re-
sidual bleeding after vascular surgery.
In a prospective randomized controlled trial, Chalmers
et al. [3], demonstrated the effectiveness of Evicel®, a
tranexamic-acid free adhesive, in achieving hemostasis
on polytetrafluoroethylene (PTFE) arterial anastomosis
within 4 min, in comparison with manual compression.
A significantly higher percentage of patients who re-
ceived fibrin adhesive achieved hemostasis within 4 min
compared with those who received manual compression
alone (85% vs 39%, p < .001), irrespective of the type of
artery treated.
Taylor et al. [8] in a single-blinded randomized pro-
spective multicenter trial investigated the safety and
effectiveness of Beriplast P® versus thrombin-soaked gel-
atin sponge (TSG) for suture needle or needle-hole
bleeding from PTFE artery grafts. On 201 subjects, 63%
of patients with fibrin adhesive achieved hemostasis
within 4 min, compared with 40% in the TSG group
(p = .0018). In the treatment group, time to
hemostasis was shorter (median, 40 min, p = .008),
and blood loss was less (median, 15 min, p = .005).
Echave and coworkers [2], in a systematic review, ana-
lyzed available data on the effectiveness of human
gelatin-thrombin matrix sealant in different surgical
fields (cardiovascular, orthopedic, otorynolaryngology,
urology). All the 27 studies included in the review dem-
onstrated that the gelatin-thrombin matrix was associ-
ated with a significantly higher rate of successful
hemostasis and a shorter time to achieve it (p < .001 for
both) in comparison with other alternatives when con-
ventional methods failed.
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Saha and coworkers [9] assessed the effectiveness of
TISSEEL® for the treatment of anastomotic suture-hole
bleeding in expanded PTFE grafts. In a prospective ran-
domized controlled study on 140 patients who experi-
enced suture-line bleeding that required treatment after
completion of anastomotic suturing, the use of TISSEEL®
brought about hemostasis within 4 min in 62.9% of sub-
jects, in comparison with 31.4% of controls (p < .001).
Similarly, hemostasis rates in the subgroup of patients
on antiplatelet therapy were 64.7% in the treatment
group and 28.2% in controls, respectively (p < .001).
Liquid fibrin adhesives are also effective as sealants, an
adjunctive measure which improves the watertight clos-
ure of the dural suture line thus preventing cerebro-
spinal fluid leak (CSF) [20–23]. Nevertheless, cautions in
using fibrin adhesive containing tranexamic acid in a
neurosurgical setting is necessary, because of its neuro-
toxicity. In fact, some evidence from preclinical studies
has shown that tranexamic acid induced hyperexcitabil-
ity and convulsions, probably caused by blocking
GABA-mediated inhibition in the central nervous sys-
tem [1, 20–23].
No incontrovertible evidence regarding the effective-
ness of liquid fibrin adhesives in preventing pancreatic,
biliary, intestinal and air leakages is available.
Chen et al. [27] in a recent systematic revision of
the literature about the use of fibrin-based products
in preventing postoperative pancreatic fistula (POPF)
following pancreatic surgery stated that the use of fi-
brin adhesives showed no significant advantages in
terms of the reduction of POPF and that they do not
decrease postoperative mortality, morbidity, or reoper-
ation rates, discouraging the routine application of
these products. Conflicting results are available on the
biliostatic effects of fibrin adhesives [1, 6, 7, 16, 17].
In a prospective randomized controlled trial on 121
patients who underwent liver resection, Schwartz
et al. [6] compared the effectiveness of Crosseal® with
that of different products, including various collagens,
cellulose, gelatin and thrombin for the control of bile
loss. The authors found that the percentage of pa-
tients who needed reoperation for biliary complica-
tions was lower in the Crosseal® group than in the
other groups (17.2% vs 36.5%, respectively; 2-sided p
= .002). No significant difference between them was
recorded about the duration of postoperative bilious
drainage, the number of patients suffering from bile
leak, the amount and duration of drainage, although
differences always favored the Crosseal® group.
Figueras et al. [17] in a prospective randomized
single-center trial on 300 hepatectomy cases found no
difference in the incidence of biliary fistula between pa-
tients treated with liquid fibrin adhesive and controls
(10% vs 11%, respectively). These results were confirmed
also by Erdogan and coworkers [16] in a systematic re-
view of the literature; the conclusion drawn was that fi-
brin adhesives cannot prevent leakages from the bile
duct on the resection surface with certainty.
Papers regarding the use of fibrin adhesives as an
adjunctive measure to prevent leakage of intestinal anas-
tomosis are lacking with conflicting results [1]. Some
suggest possible benefits in ileal and gastric/bariatric
anastomoses, while others did not find convincing re-
sults about fibrin adhesive as an external coating of co-
lonic anastomoses [25, 26].
In thoracic settings, the prophylactic use of liquid
fibrin adhesive to prevent air leak does not seem useful
if air control is good at the end of the procedure. More-
over, if fibrin adhesives are applied to control persistent
air leak at the end of conventional surgical manoeuvers,
they do not significantly reduce the time of chest tube
removal [1].
Fibrin patch
1. In addition to the previous ones, fibrin patch is
effective also in the presence of ongoing severe
hemorrhage, since it prevents the “streaming effect” of
blood (1B)
2. Fibrin patch is effective to control residual bleeding
on vascular anastomosis (1C)
3. Fibrin patch has lack effect in preventing air leakage
if complete sealing has been achieved using standard
techniques, therefore, its prophylactic use should not
be recommended (1B)
4. Weak evidences are available about the role of fibrin
patch in preventing pancreatic, biliary and urinary
leakages. Therefore, their routinely use should not be
recommended (1B)
Scientific foundation
In addition to fluid texture, fibrin adhesives are also
available as a patch (TachoSil®, Takeda; PGA-felt®, Neo-
vel; Fibrin Pad®, Omrix Biopharmaceuticals). These
products have different compositions but the same
advantages compared with fluid formulations, that are
represented by the mechanical support offered by colla-
gen or oxidized cellulose/polyglactin 910 matrix, bound-
ing coagulation factors, which allow a better adherence
to bleeding tissues, irrespective of brisk bleeding, pre-
venting the “streaming effect” observed with fluid adhe-
sives [10–15].
TachoSil® is a ready-to-use fixed combination hemostatic
agent, consisting of a white honeycomb-like equine colla-
gen patch coated with coagulation factors, human fibrino-
gen, and human thrombin on one side (yellow colored with
riboflavin for orientation).
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Fibrin Pad® and PGA-felt® are absorbable hemostats
composed of well-characterized material (polyglactin
[PG 910], oxidized regenerated cellulose, thrombin and
fibrinogen) designed to be effective in a variety of tissue
types and across a spectrum of bleeding intensities [10].
These products have all been proven to be effective
in rapidly achieving hemostasis in severe bleeding
during abdominal, retroperitoneal and pelvic surgical
procedures, compared to the standard of care [10–
12]. TachoSil® has also been employed as
reinforcement for the sutured anastomosis of the por-
tal vein and has been shown to be useful in the re-
pair of hepatic artery pseudoaneurism [15]. It has also
been proven to be effective in cardiovascular surgery.
Maisano et al. [13] in a randomized, parallel-group,
multicenter trial demonstrated that TachoSil® was sig-
nificantly superior to standard hemostatic fleece in
controlling bleeding after insufficient primary
hemostasis, with 75% of patients in the TachoSil®
group achieving hemostasis at 3 min compared with
only 33% of the standard treatment group (p < .001).
On the other hand, the effectiveness of fibrin patch in
preventing air leaks after thoracic surgery procedures,
and of pancreatic and bile leaks after resective interven-
tions is a matter of discussion.
Anegg and coworkers [31] in a randomized study on
173 patients who had undergone a lobectomy or seg-
mentectomy and were suffering from persistent air leak-
age demonstrated a significant reduction of
intraoperative air leak after application of TachoSil®
(153.32 ml/min vs 251.04 ml/min, p = .009) in compari-
son to the control group. This reduction in air leakage
volume resulted in a significant shortening of the drain-
age period (5.1 days vs 6.3 days, respectively; p = .002)
and time to discharge (6.2 days vs 7.7 days, respectively;
p = .01).
On the other hand, Belda-Sanchis et al. [32] in a
systematic literature review demonstrated that if a
complete sealing has been reached using standard tech-
niques, the prophylactic use of fibrin patch to prevent
postoperative air leaks is not justified.
Considerations for the use of fibrin patch in the pre-
vention of bile and pancreatic leakages is controversial
with a plethora of studies supporting both sides of the
argument [15].
TachoSil® has been found to be more effective in
decreasing bile leak after adult liver transplantation than
fibrin glue applicated on the cut surface (6.25% vs
43.75%, respectively; p = .03) [15].
On the other hand, Kobayashi et al. [18], in a multi-
center randomized controlled trial involving 786 patients
who had undergone hepatectomy, compared the effect-
iveness of PGA felt® (PGA-FS) versus fibrinogen-based
collagen fleece (CF) at the liver cut surface for the
prevention of bile leakage. They observed no significant
differences between the two groups, recording a bile
leakage rate of 4.1% in PGA-FS vs 5.1% in CF, respect-
ively; p = .51). Due to the heterogenicity of available evi-
dence, the routine use of fibrin patch in this setting
should not be recommended.
Conflicting data are also available on the effective-
ness of fibrin patch in preventing pancreatic fistula
after major pancreatic resections [27–29]. Montorsi
and coll [27] in a prospective, open, randomized
study on 275 patients requiring distal pancreatectomy
(DP) compared the fistula rate between patients in
whom TachoSil® was applied on the pancreatic stump
and those who did not received the fibrin patch. The
authors observed no significant difference between
the groups (62% treatment group vs 68% controls, re-
spectively; p = .276). A significantly lower amylase
concentration in the drainage was found in the
TachoSil® group on postoperative day 1, but increas-
ing on day 3 and 5, becoming similar to that re-
corded in the control group. Marangos et al. [28] in a
retrospective analysis of prospectively collected data
on 121 patients who had undergone DP found that
covering the pancreatic stump with TachoSil® did not
affect either the occurrence of POPF or duration of
postoperative hospital stay. Finally, Cheng et al. [29]
in a Cochrane revision of the available literature
stated that considering the lack of effect on the pre-
vention of POPF, high costs, and the potential harm
for endocrine pancreatic function, fibrin patch should
not be recommended routinely for people undergoing
pancreatic surgery.
Table 3 summarized the referral papers for topic 1.
Mechanical hemostats
1. Mechanical hemostats are only appropriate for
patients with an intact coagulation system (1A)
2. These agents can be used, in patients without
coagulation disorders, to improve control of residual
oozing (1A)
3. Non-regenerated oxidized cellulose-based topical
hemostats are more effective, but unhandy compared
with regenerated ones (1B)
4. The minimum effective amount of oxidized
cellulose-based topical hemostatic should be used,
and excess material not contributing to hemostasis
should be removed, because of the risk of foreign
body reactions (1A)
5. The use of oxidized cellulose-based topical hemostats
is not indicated to control biliary, urinary, pancre-
atic, and air leakages (1A)
6. Oxidized cellulose-based topical hemostats should
not be left in place in proximity to nerves, ureters,
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Table 3 Reviewed papers for adhesives
Year Design Comments GoR-
LoE
Annegg U
et al. [31].
2007 Ranzomized,
single-center
The use of TachoSil® after pulmonary resection resulted in reduction of air leak with
significant shortening of time of tube removal and of hospital length of stay
1C
Belda-Sanchis
et al. [32]
2010 Cochrane review Surgical sealants have some beneficial effects in reducing postoperative air leaks, but their
systematic use cannot be recommended at the moment
1A
Briceno et al.
[24]
2010 Prospective
controlled
The fibrin sealant after major liver resection was effective for decreasing drainage volume;
postoperative blood transfusion requirements; moderate to severe postoperative
complications and mean hospital stay
1C
Chalmers et al.
[3]
2010 Prospective
randomized
Tranexamic acid-free fibrin sealant is safe, and significantly shortened the time to haemostasis
in vascular procedures using PTFE
1B
Chapman et al.
[4]
2007 Phase 3, randomized,
double-blind
Recombinant thrombin has comparable efficacy, a similar safety profile, and is considerably
less immunogenic than bovine thrombin when used for surgical hemostasis
1C
Cheng et al.
[29]
2016 Cochrane review Considering the lack of effect on prevention of POPF, high costs, and the potential harms for
endocrine pancreatic function, fibrin sealants should not be recommended routinely for
people undergoing pancreatic surgery
1A
Colombo et al.
[14]
2014 Systematic review TachoSil® has a role as a supportive measure to improve hemostasis and promote tissue
sealing when standard techniques are insufficient
1B
Cormio et al.
[33]
2012 Prospective
randomized
TachoSil sealed tubeless PCNL does not reduce pain and analgesic requirements, but it
significantly reduces urinary leakage and postoperative hospital stay
2A
De Boer et al.
[19]
2012 Systematic review Fibrin sealants can be effective as an adjunct to achieve hemostasis during liver resections.
However, considering lack of evidence on the efficacy of fibrin sealants in reducing
postoperative resection surface-related complications, routine use of fibrin sealants in liver
surgery cannot be recommended.
1B
Dhillon et al.
[1]
2011 Systematic review Liquid fibrin sealants are effective as adjunctive measure to improve hemostasis 1B
Echave et al.
[2]
2014 Systematic review Floseal® showed improvement over other hemostatics agents in achieving hemostatis and
reducing blood loss
1B
Erdogan et al.
[16]
2007 Systematic review There is no clear proof of the biliostatic efficacy of topical hemostatic agents used after liver
resection on the resection surface
1B
Esposito et al.
[23].
2016 Systematic review Fibrin sealants provide a higher rate of intraoperative watertight closure of dura suture line
and they may be effective in preventing cerebrospinal fluid leaks with an acceptable safety
profile
1B
Figueras et al.
[17]
2007 Prospective
randomized
Application of fibrin sealants in the raw surface after hepatectomy does not seem justified 1C
Filosso et al.
[30]
2013 Prospective
randomized
TachoSil® was superior to standard stapling and suturing aerostatic techniques in reducing
postoperative air leaks in patients undergoing redo thoracic surgery.
1B
Fisher et al.
[5]
2011 Randomized,
multicenter
Tranexamic acid- and aprotinin-free fibrin sealant is safe and effective for achieving
hemostasis in soft tissue during elective retroperitoneal or intra-abdominal surgery.
1B
Fisher et al.
[10]
2013 Prospective
randomized
Fibrin pad is superior to absorbable hemostat in soft-tissue bleeding control and is safe and
effective for rapidly and reliably achieving hemostasis
1B
Genyk et al.
[12]
2016 Multicenter
randomized
open-lable
The FSP (TachoSil®) was safe and superior to ORCG (Surgicel Original) for achieving
hemostasis in patients undergoing hepatic resection
1B
Green et al.
[22]
2015 Multicenter,
prospective
randomized
Fibrin sealant is effective as an adjunct to dural sutures to provide watertight closure of the
dura mater in neurosurgery
1C
Jankowitz et al.
[21]
2009 Retrospective The use of fibrin glue for dural repair did not significantly decrease the incidence of a
persistent cerebrospinal fluid leak
2A
Kobayashi
et al. [18]
2016 Multicenter
randomized
Fibrin sealant with polyglicolic acid compared with collagen fleece did not reduce biliary
leakage and hemorrhage
1C
Koea et al.
[11]
2015 Randomized
controlled
The FP is safe and superior to SoC for controlling challenging severe soft-tissue bleeding en-
countered during intra-abdominal and thoracic surgical procedures
1C
Maisano et al.
[13]
2009 Randomized
controlled
TachoSil® was significantly superior to standard haemostatic fleece material in obtaining
effective and fast intra-operative haemostasis in cardiovascular surgical procedures. TachoSil
was safe and well tolerated.
1B
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intestinal and vascular structures, because of the risk
of ischemia due to compression or local inflamma-
tory reaction (1C)
7. Oxidized cellulose-based topical hemostats can be
used as a complementary adjunct to packing to
control bleeding from parenchymal injuries (2C)
8. Gelatins may induce, due to their swelling, a
compression of other nearby anatomic structures;
thus the minimal amount of agent to achieve
hemostasis should be used (1C)
9. Caution should be used with bovine collagen-based
products during surgical procedures that involve
blood-saving devices, because the agents can pass
through the filters (1C)
10. Caution should be used with plant-derived polysac-
charides in diabetic patients, because amounts
greater than 50 g could affect the glucose load (2A)
Scientific foundation
Mechanical hemostats include oxidized cellulose, gelatin,
collagen and plant-derived absorbable products which
promote platelet activation and aggregation when
directly applied to the bleeding surface, absorbing fluid
several times their own weight. This mechanism of ac-
tion produces a matrix at the site of bleeding, activating
the extrinsic clotting pathway which allows the clotting
to occur. Mechanical hemostats rely on fibrin produc-
tion to achieve hemostasis; therefore, these agents are
only appropriate for patients who have an intact coagu-
lation cascade [35]. Some studies [35, 36] demonstrated
that mechanical hemostats failed to induce platelet acti-
vation in the absence of plasma constituents, especially
factors VIII and XII. In patients with a functional intact
coagulation system these agents can be used as first-line
agents because of their immediate availability and as
they are highly cost-effective [35–38]. They represent a
useful adjunct, with a direct pressure on the bleeding
site, to control minimal residual hemorrhage [35].
Oxidized cellulose (OC) (Surgicel®, Surgicel Fibrillar®,
Surgicel Nu-Knit®, Johnson & Johnson) is well known and
accepted because of its ease of use, favorable biocompati-
bility and bactericidal properties. Cellulose is a homopoly-
saccharide which is created through polymerization of
glucopyranose through β-glucosidic bonds. Oxidized cel-
lulose can be either regenerated (ORC), in which orga-
nized fibers are formed prior to oxidation or
non-regenerated (ONRC), with unorganized fibers priors
to oxidation. Non-regenerated oxidized cellulose has
frayed fibers, while regenerated oxidized cellulose has con-
densed fibers. ORC is thought to conform more rapidly to
the surrounding environment. However, Lewis et al. [36]
described superior hemostasis for ONRC, with equivalent
bactericidal effectiveness, when compared to ORC. In a
nonheparinized porcine hepatic square model ONRC pro-
vided superior shorter median time to hemostasis than
ORC (211.2 vs 384.6 s) and at 10 min after application the
Table 3 Reviewed papers for adhesives (Continued)
Year Design Comments GoR-
LoE
Montorsi et al.
[27]
2012 Multicenter
randomized
controlled
TachoSil® had no significant effect on the rate of POPF, although there was a significant
reduction of amylase level in drainage fluid on postoperative day 1.
1B
Marangos et al.
[26]
2011 Retrospective The application of the TachoSil® patch did not affect either occurrence of POPF or duration of
postoperative hospital stay. Routine use of TachoSil® patch to prevent pancreatic fistulas does
not provide clinically significant benefit.
1C
Perussi Biscola
et al. [20]
2017 Systematic review The new heterologous fibrin sealant from snake venom represents a consistent alternative to
biological sealants, since they may avoid transmission of infectious diseases
1C
Pommergaard
et al. [26]
2013 Systematic review Liquid fibrin adhesive should be beneficial to prevent leak of ileal anastomoses in gastric and
bariatric surgery
1C
Saha et al.
[9]
2012 Prospective
randomized
Fibrin sealant is safe and its efficacy is superior to manual compression for hemostasis in
patients with vascular ePTFE graft
1C
Schwartz et al.
[6]
2004 Prospective
randomized
controlled
Crosseal fibrin sealant significantly reduces the time of hemostasis following liver resection in
comparison with the standard topical hemostatic agents
1C
Simo et al.
[15]
2012 Systematic review Application of TachoSil® in hepatobiliary and pancreatic surgery has proven effectiveness in
hemostasis and as tissue sealant
1C
Spotniz et al.
[7]
2012 Systematic review Fibrin sealants have multiple new uses that should result in further improvement in patient
care
1C
Taylor et al.
[8]
2003 Randomized
prospective
multicenter
Fibrin sealants are more effective than thrombin-soaked gelatin sponge for achieving
hemostasis of needle or suture hole bleeding from PTFE femoral artery grafts.
1B
Vakalopoulos
et al. [25]
2012 Systematic review Fibrin sealant seem not be necessary as external coating of colonic anastomoses to prevent
leakage
1C
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hemostatic success, defined as no bleeding, was greater in
the ONRC than in the ORC (100% vs 96.6%). In the same
study, ONRC provided superior hemostasis in a heparin-
ized leporine femoral bleeding model in comparison with
regenerated cellulose. In particular, the hemostatic success
at 90s after application was 97.5% for ONRC and 70% for
ORC.
Minimal use of oxidized cellulose for effective
hemostasis and maximal cleaning of field from residual
agents after achievement of hemostasis is warranted. Al-
though OC can be absorbed in 2–5 weeks, depending on
the amount used, degree of saturation with blood and the
tissue bed, the excess of material may also cause granula-
tion formation without bio-degradation in the late
post-operative period, and this result may complicate the
radiological and clinical differential diagnosis of abscess,
residual/recurrent tumors and granuloma [37, 38, 68].
Sabino et al. [37] demonstrated in a series of laparoscopic
partial nephrectomies (LPN) that the use of OC was asso-
ciated with an intense foreign-body reaction, strongly
present at day 4,7 and 21 post-op. Tissue at 21 days in a
group treated with OC was grossly solid, apparently a
granuloma. Notwithstanding OC’ low pH may exert a bac-
tericidal effect, in this study suppuration was higher in the
group treated with OC, probably because the existence of
residual material may serve as a bed for microorganisms
in the late period, particularly in a heme-rich environ-
ment. Moreover, at day 7 post-op, the incidence of urinary
fistula was higher in the presence of OC. Similarly, Agar-
wal [68] and coworkers have shown that after laparoscopic
nephron-sparing surgery using Surgicel bolster for
hemostasis, foreign-body reaction leading to the formation
of pseudotumor was observed at 3 month magnetic reson-
ance follow-up, which leads to a diagnostic dilemma.
While OC devices are designed to stimulate clot for-
mation and to provide a favorable three-dimensional
structure for clot organization, there is no evidence that
they are useful in preventing biliary, pancreatic and air
leaks.
Other safety considerations include potential paraly-
sis and nerve damage when OC is used around, in or
in proximity to foramina, areas of bony confine, the
spinal cord, the optic nerve and chiasm [69].
Menosky et al. [69], demonstrated in a case series of
decompression of high-grade spinal stenosis that the
swelling of small portions of Surgicel Fibrillar, used to
control bleeding from epidural venous plexus, led to
a significant mass effect one day after surgery, causing
a rapid neurological deterioration. Moreover, a sten-
otic effect when ORC has been applied as a wrap
during vascular surgery or urologic procedure has
been described [69]. Although it has not been estab-
lished that the stenosis was directly related to the use
of cellulose-based products, it is important to be
cautious and avoid applying the material tightly as a
wrapping.
The effective deployment of cellulose-based products
may prove difficult in wet environments, as a result of
poor adhesion to tissue in this setting. Frequently, the
application of adequate pressure at the site of
hemorrhage is required to provide the tamponade neces-
sary to facilitate their effectiveness. For this reason, OC
may be intended for use as an adjunct to gauze packing,
paying attention to remove the excess material not con-
tributing to hemostasis at reoperation, after damage con-
trol [39].
Other mechanical hemostats are represented by
gelatin-based devices, prepared from purified pork
skin gelatin or bovine derived gelatin. They are highly
absorptive and provide a mechanical matrix for the
clot to adhere. They act at the end stage of the
coagulation cascade to facilitate fibrin formation, pro-
moting coagulation and minimizing blood loss, from
oozing to spurting [2]. They are available in sponge,
powder and granular forms. Gelatin formulations are
able to adjust to irregular wounds and surgical cav-
ities. Because the pH of gelatin-derived devices is
neutral, they can be used in conjunction with throm-
bin and these products belong to the category of ad-
hesives (FloSeal® Baxter Healthcare Corporation,
Fremont CA, USA; Surgiflo® Johnson & Johnson
Company, NJ, USA).
Once applied, gelatin-based agents are completely
reabsorbed within 4–6 weeks. Attention must be paid
to use the minimal amount of agent to achieve
hemostasis and to remove excess product after
hemostasis has been achieved, because the swelling
could result in compression and necrosis of the sur-
rounding tissue if the product is packed or wadded,
especially within bony spaces [2].
Similarly, bovine-collagen based products act by
forming a physical matrix that encourages clot by
stimulating platelet aggregation and the release of
clotting factors.
The use of collagen-based and gelatin-based products
has led to a significant reduction in both intraoperative
blood loss and postoperative transfusions. The effective-
ness of these two types of products has been compared
in a recent randomized controlled trial performed by Xu
et al. [40] on 92 patients who had undergone spinal
fusion surgery. The authors concluded that
collagen-based products demonstrated better hemostatic
effect than gelatin-based products, with lower blood loss
and postoperative drainage volume.
Caution must be paid when blood-saving devices are
required during surgical procedures, because the parti-
cles of bovine-collagen based product pass through the
filters [1].
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Microporous polysaccharide hemospheres (MPH), a
new generation hemostatic agent (Arista™ AH; Medafor
Inc., Minneapolis, MN), are derived from plant starch in
the form of a powder. It absorbs water and low molecu-
lar weight compound from blood to concentrate plate-
lets and clotting proteins as its beaded surface while
enhancing endogenous clotting processes [38, 41]. Its
safety and efficacy have been shown in many tissues.
Bruckner et al. [41] in a retrospective study tested the
product on 240 patients who had undergone cardiothor-
acic procedures (heart transplantation, cardiac assist
devices, coronary artery bypass grafts, valve procedures,
lung transplantation, aortic dissection and others). The
application of Arista™ AH led to significant reduction in
hemostasis time versus the untreated control group
(Arista™ AH 93.4 ± 41 min vs Control 107.6 ± 56 min; p
= 0.02). Postoperative chest drain ouptut during the first
48 h was also significantly reduced (Arista™ AH 1594 ±
949 mL vs Control 2112 ± 1437 mL, p < .001), as well as
packed red blood cells transfusion requirements (Arista™
AH 2.4 ± 2.5 units vs Control 4.0 ± 5.1 units; p < .001).
Emmez and coll [38] demonstrated that Arista™ AH, in
comparison with ORC, provided a safe and effective
hemostasis in a model of brain hemorrhage. Moreover,
Arista™ AH was found to be completely re-absorbable
within a couple of minute, therefore it does not appear
to represent a nidus for infection or granuloma forma-
tion [41]. Safety concerns include the risk of embolism if
accidentally injected or placed within blood vessels and
its use on diabetic patients. In this last setting, no more
than 50 g of product should be used, because amounts
in excess of 50 g could affect the glucose load [41].
Table 4 summarized referral papers for topic 2.
Sealants
1. Sealants encompass a variety of heterogeneous but
non-equivalent products (1A).
2. Sealants are effective, irrespective of patient’s
coagulation status, to improve control of residual
oozing (1A)
3. Polyethylene glycol-based sealants are effective, as an
adjunctive measure, to improve hemostasis on vascu-
lar anastomosis, to control air and cerebrospinal
fluid leakages (1B)
4. Polyethylene glycol-based sealants must not be used
in cases of known or suspected allergy to human al-
bumin or renal insufficiency (1A)
5. The use of cyanoacrylate-based adhesives must be
avoided both in contact with brain tissue because of
the risk of foreign body reaction, and inside the ves-
sels, because of thrombotic risk, except for interven-
tional radiology or endoscopic procedures (1A)
6. Weak evidences are available regarding the
effectiveness of fibrin glue to prevent biliary, urinary
and air leakages (1B)
7. Albumin-based sealants are effective to improve
hemostasis on vascular anastomosis, but
Table 4 Reviewed papers for mechanical hemostats
Year Design Comments GoR-
LoE
Agarwal et al.
[68]
2010 Case series Excessive amount of oxidized cellulose may induce granuloma 2C
Broadbelt
et al. [39]
2002 Case series Excessive amount of cellulose in confined space like foramina may induce compression of
spinal cord because of swelling
2C
Bruckner et al.
[41]
2014 Retrospective The use of polysaccharide hemospheres absorbable hemostat in complex cardiothoracic
surgery resulted in significant reduction in hemostasis time, postoperative chest tube output,
and need for postoperative blood transfusion
2A
Emmez et al.
[38]
2010 Experimental in vivo Microporous polysaccharides spheres may be used for hemostasis in neurosurgical setting,
without inducing granuloma
2A
Lewis et al.
[36]
2013 Experimental in vivo-
in vitro preclinical
Oxidized non-regenerated cellulose provides superior hemostasis and equivalent bactericidal
effectiveness relative to oxidized regenerated cellulose
2C
Menovsky
et al. [69]
2011 Case reports Removal of Surgicel® Fibrillar™ is advised after hemostasis has been achieved to avoid the
development of complications due to a mass effect
2C
Ragusa et al.
[34]
2007 Randomized
prospective
Absorbable gelatin in association with antibiotic is effective in reduce bleeding and
infectious complications after cardiac surgery
2A
Sabino et al.
[37]
2007 Retrospective 2B
Wagenhauser
et al. [35]
2016 Experimental
preclinical
Stronger inhibition of essential cellular processes of wound healing were observed for
Oxidized non-regenerated cellulose when compared with oxidized regenerated cellulose
2C
Xu et al.
[40]
2016 Randomized
controlled
Hemostatic collagen sponge demonstrated better hemostasis effects than gelatin sponge
with lower volume of postoperative drainage volume and blood loss in posterior spinal
fusion
2A
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circumferential application must be avoided because
of the risk of stenosis (1B)
8. Albumin-based sealants are effective to control
cerebrospinal fluid leakage (1B)
Scientific foundation
Sealants encompass a wide variety of products that
are able to form a barrier to leakage and bleeding
through covalent polymerization between themselves
and adjacent tissues. These products differ one from
another for the mechanism of action, field of use and
warning against use. The ideal sealant should be
strong, flexible, rapid to adhere, sterile, without tox-
icity, biologically inert, completely biocompatible, able
to be used in a relatively wet environment and with
low thrombogenicity.
Fibrin-based adhesives [2, 16–23] also have a sealant
effect due to the polymerization of fibrin monomers. In
this case the hemostatic effect is predominant, because
it depends entirely on the concentration of the fibrino-
gen, of the factor XIII and fibronectine, whereas that of
the sealant is frail. The sealant effect of fibrin glues has
been investigated in a wide variety of surgical fields [2].
The most widely investigated is liver surgery because bil-
iary leakage, although not very frequent, remains a prob-
lem with a reported incidence ranging from 3.6% up to
12% [16]. Postoperative biliary leakage may result in ab-
dominal sepsis and even postoperative mortality. Unfor-
tunately, results are conflicting. While some studies [16,
19] indicate that fibrin sealants may have a potential role
in sealing bile ducts, thereby decreasing the total fluid
drainage and its bilirubin concentration, others did not
[17, 18]. In particular, Figueras et al. [17] in a random-
ized study on 300 patients who underwent liver resec-
tion demonstrated that the incidence of biliary fistula
was similar in the fibrin glue and control groups (10% vs
11%), and that there were no differences in postoperative
morbidity between the groups (23% vs 23%; p = 1). Simi-
larly, scant evidence is available regarding the effective-
ness of fibrin glue in preventing urinary leakage [2].
Fibrin glue has been the most widely used sealant mater-
ial in thoracic surgery over the last 10 years. Moreover,
several randomized trials and systematic reviews [32]
demonstrated that there was no difference between
treatment and control groups in terms of postoperative
air leaks, duration of chest drain and in hospital length
of stay, therefore discouraging its systematic use.
True sealants (“cross-linking”) can be divided into syn-
thetic (PEG-polyethylene glycol-based and cyanoacrylate)
[40–46] and semi-synthetic (glutaraldheide-albumin) [49].
In contrast to fibrin glue, cross-linking sealants polymerize
through a non-enzymatic chemical reaction, which do not
require the presence of blood or any components of the
coagulation cascade. The presence of coagulation factors
within the fibrin glue and, on the other hand, the ability of
the cross-linking sealants to act even in cases of failure of
the coagulation cascade, make both these products effect-
ive, irrespective of the patient’s coagulation status, as ad-
junctive measures to improve control of residual mild
hemorrhage (oozing) [44, 46, 47].
Polyethylene-glycol-based (PEG) sealants are manufac-
tured both as pads of different sizes (Hemopatch® Baxter
AG, Vienna, Austria; Veriset™ Covidien Inc., Mansfield,
MA, USA) and as flowing products (DuraSeal®, Integra
LifeSciences, Plainsboro, NJ; Progel®, Neomend Inc.,
Irvine, CA). Available pads can be composed of a syn-
thetic, protein-reactive monomer (NHS-PEG) and a
collagen backing (Hemopatch®), or of an oxidized cellu-
lose backing impregnated with buffer salts, trilysine and
PEG derived from non-animal sources (Veriset™) [44, 46,
47]. Several studies demonstrated the effectiveness of
both products as sealants and hemostats in different
settings. Imkamp and coworkers [44] were the first to
provide a clinical report on the effectiveness of Hemo-
patch® in a seven-patient case series on laparoscopic,
zero-ischemia partial nephrectomy (LPN). In four of the
seven patients no hemostatic under-suture was used fol-
lowing sealant application; in all patients the postopera-
tive course was uneventful, and no leakages were
observed. In other series, Hemopatch® was effectively
used for hemostasis and sealing after coronary artery
grafting, resection of the interventricular septum and
aortic and mitral valve replacement while on cardiopul-
monary bypass [44]. The product was used to treat the
dissected myocardial tissue and the anastomotic suture
lines, without any appearance in the postoperative
period of pericardial effusion or pseudoaneurysm sug-
gestive of hemostatic failure. Moreover, the effectiveness
of this product depends entirely on the presence of a
proteinaceous fluid to form a hydrogel, which effectively
adheres and seals tissue surfaces [44], but limits its use
on dry environment.
In a multicenter, randomized, single-blind clinical
trial on 50 patients, Ollinger et al. [48] demonstrated
the effectiveness of the oxidized cellulose-PEG-based
sealant Veriset™ in achieving hemostasis after open
hepatic surgery faster than the control device (median
time to hemostasis:1.0 min vs 3.0 min, p < .001), irre-
spective of the size of the raw surface (bleeding
sites≥100cm2, median time to hemostasis:1.0 min vs
4.0 min, p = 0.033).
Flowing products are easier to handle and effective to
control air leakage during thoracic surgery and water-
tight closure of dural opening occurring during spine
surgery. In a multicenter prospective randomized trial
on 161 patients undergoing pulmonary resection, Allen
and coworkers [49] demonstrated that a synthetic PEG
component in a solution of human albumin (Progel®)
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effectively sealed intraoperative residual air leaks after
standard methods (staples, sutures, or cautery) in 77% of
patients compared with 16% in the control group using
standard methods alone (p < .001). In addition, fewer
patients in the Progel® group had postoperative leaks
versus the control group (65% vs 85%). On the other
hand, only preclinical studies are available on the effi-
cacy on air leak control of other products, such as
Hemopatch® [44]. Therefore, further studies to investi-
gate pneumostatic ability of this device are warranted.
Dural openings occurring during spine surgery, either
intentionally to access the intradural contents, or unin-
tentionally during extradural decompression, need
watertight closure whenever possible to prevent poten-
tially significant complications (postural headache,
vomiting, dizziness, photophobia, tinnitus, and pseudo-
meningocele). Kim and al [45], in a prospective multi-
center study on 158 subjects, demonstrated that patients
treated with the PEG hydrogel sealant, in addition to
standard measures of dural closure, had a significantly
higher rate of watertight closure than that of the con-
trols (100%vs 64.3%, p < .001), without statistical differ-
ences in postoperative cerebrospinal fluid leaks,
infections, and wound healing. Although neither compli-
cations nor neurological consequences related to sealant
were observed in the pivotal study [45], the risk of nerve
compression due to swelling of PEG after application is
present. For this reason, a new low-swell PEG hydrogel
sealant (Duraseal) formulation is now available. Wright
and coworkers [46] recently confirmed in a prospective,
3:1 randomized, single-blind multicenter investigational
study that this new low-swelling formulation is safe and
effective, watertight dural closure having been immedi-
ately achieved in 100% of the study patients treated with
the hydrogel. The rate of complications was comparable
between spinal sealant (6.8%) and controls (8.3%), and
no device-related adverse events were recorded.
Safety considerations with PEG-based sealants in-
clude the risk of impaired renal function, due to the
renal clearance of the polyethylene glycol. For this
reason, PEG-based sealants should not be used in
cases of known renal insufficiency. PEG-based formu-
lations containing serum albumin may induce allergic
reactions in patients sensitive to human serum albu-
min or other device components. Furthermore, the
potential risk of transmission of communicable dis-
eases or viruses from the human serum albumin
component is not completely absent.
Cyanoacrylates are synthetic sealants that rapidly
polymerize in the presence of water which acts like a cata-
lyst. Two formulations are available: octyl-2-cyanoacrylate
(Dermabond, Johnson & Johnson), and N-butyl-2 cyano-
acrylate (Indermil, Covidien), possibly in association with
metacryloxysulpholane monomer (Glubran 2, GEM). In
general, these agents are best suited for topical dermal use
for the closure of skin incisions or lacerations where there
is low skin tension. A systematic review of the available lit-
erature [42] did not show any difference in dehiscence,
infections or satisfaction with cosmetic appearance when
repairing lacerations using octyl-2-cyanoacrylate com-
pared with standard sutures, staples or adhesive strips. If
applied below the skin, foreign body reaction can occur
[42]. Moreover, heavy application of sealant should be
avoided because the polymerization process generates
heat, inducing thermal damage. For this reason, use of the
product in contact with frail tissue such as brain tissue
must be discouraged. Similarly, because of the well-known
risk of post-injection systemic embolization of the glue
material, intravascular use of the product should be
avoided. The only settings where the endovascular use of
cyanoacrylate has been demonstrated to be safe are endos-
copy [50] and interventional radiology [51]. Belletrutti and
coworkers [50] in a retrospective analysis of 47 consecu-
tive procedures of endoscopic gluing of bleeding varices,
achieved immediate hemostasis in 93.8% of cases, with
complete eradication of varices in 84% of patients. Only
one case of mesenteric thrombosis was observed and the
treatment failure-related mortality was 2.1%. Parildar et al.
[51] in a case series of 20 patients with visceral pseudoa-
neurysms demonstrated that N-butyl-cyanoacrylate may
be safely used to avoid proximal embolization of the vis-
ceral arteries that could not be catheterized selectively be-
cause of tortuosity, vessel size, or anatomic location. More
recently, in addition to these fields of use, the application
of cyanoacrylate glues has been reported for the manage-
ment of urinary fistula. Selli et al. [43] described a case
series of five patients suffering from iatrogenic urinary fis-
tulas, which were successfully managed by a minimally in-
vasive injection of N-butyl-cyanoacrylate, seemingly a
valid first line treatment, justified in cases when the urin-
ary output is not excessive and there is a favorable ratio
between the length and diameter of the fistulous tract.
The sealant effect of the semisynthetic
glutaraldehyde-bovine albumin based sealant (BioGlue)
is achieved by a cross-linking between proteins on the
surface of human tissue to those of bovine albumin. In
addition, in the presence of synthetic graft materials,
BioGlue adheres to them through mechanical interlocks
in the interstices of the graft matrix [52]. These proper-
ties make this sealant attractive for securing and sealing
vascular anastomotic sites, thus decreasing postoperative
bleeding. Coselli and coworkers [52] in a randomized
study on 151 patients who had undergone cardiac and
vascular procedures, demonstrated that anastomotic
hemostasis was achieved in 60.5% of patient treated with
Bioglue compared to 39.2% (p = .014) of subjects treated
with standard surgical repair. At the same time, patients
in the BioGlue group required fewer transfusions of red
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blood cells and significantly fewer reinforcing pledgets
on the primary anastomosis, compared with patients
treated with standard sutures (p = .047). Caution must
be used not to circumferentially apply the product
around the anastomosis, because of the risk of stenosis.
It seems that BioGlue led to micro pyrogranuloma,
macrophage infiltrates, and fibrosis in adventitia, indicat-
ing that the glue reacts with the tissue to contribute to
stenosis [52].
Notwithstanding some adverse effects have been rec-
ommended after application of BioGlue in the proximity
of nerves, recent experience reported by Miscusi et al.
[53] showed that BioGlue is safe and effective, even in
contact with neurological structures. The authors dem-
onstrated on 23 patients requiring dural tear repair that
the use of BioGlue was effective in achieving dural
watertight closure, avoiding cerebrospinal fluid leakage,
with no incidence of neurological or infection-related
complications.
Table 5 summarized referral papers for topic 3.
Hemostatic dressings (mineral and polysaccharides)
1. In a pre-hospital setting, topical hemostatic agents,
minerals and polysaccharides, together with manual
compression, are effective to control junctional bleed-
ing, if tourniquets are not effective or not applicable
(1B)
2. Minerals must be considered only for external use,
because of intense exothermic reaction, and kaolin-
based products should be considered as the first
choice (1B)
3. Bandages should be preferred over granules/powders
(1B)
Scientific foundation
Exsanguination following severe trauma is often poten-
tially preventable, while hemorrhage still remains an im-
portant cause of death, mostly in prehospital settings
and hostile environments [54–56]. From military experi-
ence, it is well known that the three principal sites of le-
thal hemorrhage are truncal (67%), junctional (i.e., groin,
axilla, neck) (19%) and extremities (14%) [54–62]. A re-
port from the National Trauma Databank suggests that
mortality for patients with isolated lower extremity
trauma with an arterial injury is 2.8%, with a 6.6% ampu-
tation rate [55]. Although the Hartford Consensus Con-
ference [56] encourages wider civilian use of tourniquets
for the control of significant extremity hemorrhage when
direct manual compression is ineffective or impractical,
Table 5 Reviewed papers for Sealants
Year Design Comments GoR-
LoE
Allen et al.
[49]
2004 Prospective randomized Polymeric sealants may reduce air leak after pulmonary resection 2A
Belletrutti
et al. [50]
2008 Retrospective N-butyl-2-cyanoacrylate is effective and safe for bleeding control from gastric varices 2A
Coselli et al.
[52]
2003 Prospective randomized The bovine serum albumin and glutaraldehyde sealant is a safe and effective adjunct to reduce
the occurrence of anastomotic site bleeding in cardiovascular surgery
2A
Dumville
et al. [42]
2014 Cochrane review There is some evidence that dehiscence rates may be higher in wound closed with tissue
adhesives than with sutures; there was no evidence of any difference between sutures and
tissue adhesive for outcomes such as cosmetic appearance and satisfaction
1A
Imkamp
et al. [47]
2015 Prospective Hemopatch® is effective to improve hemostasis in nephron-sparing surgery 2B
Kim et al.
[45]
2011 Prospective randomized Polyethylene glycol hydrogel spinal sealant is effective as adjunctive measure to improve
watertight closure of dura mater in spine surgery
2A
Lewis et al.
[43]
2016 Systematic review Hemopatch® is an effective, easy-to-use hemostatic agent in open and minimally invasive
surgery of patients with thrombin- or platelet-induced coagulopathies
1C
Miscusi
et al. [53]
2014 Prospective Sealants are useful for dural watertight closure 2A
Ollinger
et al. [48]
2013 Prospective multicenter Polyethylene glycol patch is useful in control of bleeding from hepatic cut surface 2A
Parildar
et al. [51]
2003 Prospective N-butyl cyanoacrylate is an useful tool for angioembolization of visceral psuedoaneurism 2A
Selli et al.
[43]
2013 Case reports N-butyl-2-cyanoacrylate represent a valid first line treatment to control urinary fistula when the
output is not excessive and there is a favourable ratio between length and diameter of
fistula tract
2C
Wright
et al. [44]
2015 Prospective, randomized
controlled, multicenter
Polyethylene glycol hydrogel sealant has been proven safe and effective for provide a
watertight closure as an adjunct to sutured closure of durotomies
2A
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also supported by the American College of Surgeons
Committee on Trauma [55], and notwithstanding junc-
tional tourniquets specifically designed for a military set-
ting are available, the management of hemorrhage in
junctional areas still represents a major concern. For this
reason, topical hemostatic agents have been listed as
optional basic equipment for ambulances [56] for the
control of significant hemorrhage in anatomic areas
where tourniquets cannot be applied and where sus-
tained direct pressure alone is not feasible.
Hemostatic agents and dressings can be classified
according to their mechanism of action, the form of the
agent, the delivery mechanism, and the type of wound.
They are classified either as factor concentrators, pro-
coagulants, or muco-adhesives.
Factor concentrators are mainly represented by prepa-
rations of zeolite, a microporous crystalline aluminosili-
cate, an inert volcanic mineral, or of smectite, a
nonmetallic clay mineral composed of sodium, calcium
and aluminum silicate, which acts by concentrating the
cellular and protein component of blood, thereby pro-
moting clot formation. A first-generation agent in this
group was the QuikClot® (QC) granules to be poured
onto the bleeding wound. A new generation product is
the QuikClot Advanced Clotting Sponge® (ACS;
Z-Medica; Wallingford, CT) which uses zeolite beads
enclosed in a loose mesh bag, allowing for a more effect-
ive application into wound cavities and easing removal
of the product during surgery. The first series of clinical
experience with QC has been described by Rhee and co-
workers [58], who reported the results of a survey on
103 patients, both in military and civilian settings. The
overall efficacy rate was 92%, with eight cases of ineffect-
iveness in coagulopathic morbid patients when QC was
used as a last resort. In the same series, 20 cases of
intra-corporeal use (thorax, abdomen, pelvis) of the
product was described, with adverse reaction repre-
sented by burns due to intense exothermic reaction and
scar formation from foreign body reaction.
QuikClot was also compared to other hemostatic
agents, such as chitosan-based HemCon®, (HemCon,
Medical Technologies Inc., Portland, OR) in a retro-
spective evaluation performed by Cox et al. [64] on
military patients injured after the explosion of impro-
vised explosive devices, or gunshot wounds. Both
agents were effective in the control of bleeding, but
QC use was burdened by burns at the sites of appli-
cation. Thermal injury resulting from zeolite use has
been described also by McManus et al. [57] in a
series of cases treated for major hemorrhage second-
ary to combat wounds. All the available data suggest
that the exothermic reaction will be greater when
more blood and more product is present at the site
of application. For this reason, only external use of
the least amount of product necessary to achieve
hemostasis is warranted [57].
Procoagulant agents enhance coagulation by providing
a high local concentration of coagulation factors. The
paramount agent is represented by QuikClot Combat
Gauze® (QCG) produced by Z-Medica (Wallingford,
CT). The product is a surgical gauze coated with kaolin,
an inert mineral that initiates the coagulation cascade
upon contact with the injured endothelium via the con-
tact pathway. It is not biodegradable so it must be re-
moved from the wound before definitive repair is
completed. Shina et al. [59], from the Israel Defense
Forces Medical Corps, retrospectively reviewed 122
cases of military patients on whom 133 hemostatic
dressings were applied. Dressings were used in 27.8% for
junctional hemorrhage control, achieving hemostasis in
88.6% of cases. For extremity injuries, hemorrhage
control was achieved in 91.9% of patients. These results
suggest that a kaolin-based product is an effective tool
for hemorrhage control for both junctional and
non-junctional injuries, with the advantage over QC of
not inducing a temperature increase in the wound.
Muco-adhesive agents are represented by
chitosan-based products HemCon®, (Medical Technolo-
gies Inc., Portland, OR); HemCon ChitoGauze®, (Hem-
Con Medical Technologies Inc); Celox®, (MedTrade
Products, UK). Chitosan refers to a series of polymers
derived from crustacean chitin and it is a complex
carbohydrate that is biodegradable. Chitosan has no in-
trinsic hemostatic properties and thus works independ-
ently of the coagulation system. The hemostatic
properties appear to be by direct electrostatic interaction
between negatively charged cell membranes of the eryth-
rocytes and positively charged chitosan. This agent dis-
plays strong adherence to tissues and physically seals
bleeding wounds [60–63]. Sixty-four combat uses of
chitosan-based product were reported by Wedmore et
al. [60], in a retrospective analysis of prehospital com-
bat casualties. In this series, dressings were utilized
externally on the chest, groin, buttock and abdomen
in 25 cases; on extremities in 35 cases; and on neck
and facial wounds in 4 cases. In 66% of patients,
dressings were utilized following gauze failure and
were 100% successful. In 97% of cases their use re-
sulted in cessation of bleeding or improvement of
hemostasis. Failure occurred in only two cases, be-
cause of blind application of bandages up into large
cavitational injuries. The largest prospective study in
a civilian setting about the use of chitosan-based
hemostatic devices (HemCon ChitoGauze®) was made
by Te Grotenhuis and coll [63]. They analyzed 66
cases of patients on whom dressings were applied if
conventional treatment (gauze with manual compres-
sion) failed to control external bleeding or if
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conventional treatment was unlikely to achieve
hemostasis. Twenty-one patients were taking antico-
agulants or suffered from a clotting disorder. In this
study, HemCon ChitoGauze® completely stopped
hemorrhage in 70% and reduced hemorrhage in 20%
of the patients. The cessation of hemorrhage was
observed more often in patients with arterial
hemorrhage (p = 0.0031). The result was not affected
by coagulopathy and no adverse effects were
recorded.
A safety concern pertains to the risk of adverse
events induced by the use of chitosan-based devices
in patients allergic to crustaceans. Waibel et al. [61]
in 2011 tested for the first time the safety of Hem-
Con® bandage in shellfish allergic subjects. Nineteen
patients were recruited, all of whom demonstrated
shrimp-specific IgE, but none had a skin prick test
(SPT) positive to chitosan powder or experienced an
adverse reaction during bandage challenges. No other
studies using chitosan bandages have reported any al-
lergic response to the agent. Nevertheless, although
multiple reports on the use of chitosan in clinical set-
tings exist, evidence for the safety of chitosan dress-
ing is encouraging but not conclusive [55].
Taking into account all the aforementioned aspects
regarding the different agents, mostly pertaining to
potential adverse effects associated with their use, and
whereas tourniquet application should be the initial
and principal method for extremity hemorrhage con-
trol, kaolin-based QCG may be considered as the ini-
tial tool for junctional zone hemorrhage control.
Undoubtedly the treatment and coverage of a complex
and irregular wound with multiple bleeding sites is eas-
ier when granular agents are used, however granular ma-
terials are more difficult to handle and apply effectively,
especially in hostile conditions [62]. In addition, the ma-
jority of granular agents are not bio-absorbable and
therefore must be removed from wounds by saline
flushes or tissue debridement before surgical repair can
be performed.
Moreover, as Kheirabadi and coworkers demon-
strated in a preclinical study [62], there is a potential
risk for some small particles to enter the vascular sys-
tem and become a source of thrombosis upon blood
reflow. For these reasons, bandage/gauze format that
allows packing of the wound, should be preferred as
being safer and able to induce a superior hemorrhage
control [55].
Table 6 summarized the referral papers for topic 4.
Conclusions
In conclusion, local hemostatic agents are different
products with distinctive indications. A knowledge of
the properties of each single agent should be in the
armamentarium of acute care surgeons in order to se-
lect the appropriate product in different clinical
Table 6 Reviewed papers for Hemostatics Dressing
Year Design Comments GoR-LoE
Bulger et al.
[55]
2014 Guidelines Topical hemostatic agent in combination with direct pressure are effective for bleeding control in
pre-hospital settings in anatomical areas where tourniquet cannot be applied
1A
Cox et al.
[64]
2009 Retrospective
cohort study
HemCon appears to be safe, while QuickClot may produce superficial burns. These products
should be taken into account to assist in controlling internal hemorrhage, especially during
damage control surgery
2C
Jacobs et al.
[56]
2013 Guidelines Wider civilian use of tourniquet should be encouraged for the control of significant extremity
hemorrhage when direct manual compression is ineffective or impractical
1A
Kheirabadi
et al. [62]
2009 Experimental,
animal
The hemostatic agents are more effective and safe than the currently deployed devices in controlling
arterial hemorrhage
2A
Leonard et al.
[54]
2016 Retrospective,
multicenter
QuickClot is an effective and safe adjunct to control hemorrhage in prehospital setting 2A
McManus [57] 2007 Case series Zeolite, despite potential complication of thermal injuries, has shown to be a valuable hemostatic
agent if used under appropriated circumstances
2C
Rhee et al. [58] 2008 Case series QuickClot has been proven safe and effective to control prehospital non compressible
hemorrhage
2A
Shina et al. [59] 2015 Retrospective Hemostatic dressing seem to be an effective tool for junctional hemorrhage control and should
be considered as second-line treatment for extremity hemorrhage control at the point of injury
1C
Te Grotenhuis
et al. [63]
2016 Prospective Chitogauze is an effective and safe adjunct in the prehospital traatment of massive external
traumatic hemorrhage
1C
Waibel et al.
[61]
2011 Prospective Chitosan bandage is safe even in shellfish allergic patients 2C
Wedmore et al.
[60]
2006 Retrospective Chitosan-based hemostatic dressing is useful for prehospital combat casualties 2C
ORC oxidized regenerated cellulose, ONRC oxidized non-regenerated cellulose
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conditions. The aim should be to stop the bleeding as
soon as possible, to avoid the consequences of pro-
longed blood loss on body physiology.
The first concern (Fig. 2) of the surgeon should be
the state of the endogenous coagulation system of the
patient. If it is normal, a mechanical agent as adjunct
to surgical hemostasis or packing is sufficient and
cost-effective. If coagulation cascade does not work,
in relation to the current disease or drug-induced
dysfunction, the choice should be an agent that is
also effective without coagulation factors, such as ad-
hesive products. In the case of ongoing arterial or
high flow bleeding, a patch-supplemented adhesive
agent is easier to use because of its direct applicabil-
ity under pressure on the site of the blood loss.
When the bleeding source is a parenchymal section
(liver, pancreas, kidney) or the objective is an airtight
closure of a lung wound, the choice of a sealant agent
is a valuable option. Finally, in pre-hospital settings,
hemostatic dressings should be considered in junc-
tional and non-compressible hemorrhages (neck,
groin, axilla), kaolin-based products being the first
choice.
From this systematic review it is clear that in acute
care surgical services all categories of agents, mechan-
ical, adhesives, adhesives with patch and sealants
should be available because of their different usages
and indications. On ground and air ambulances, as
well as tourniquets and conventional bandages, ad-
vanced hemostatic dressings should be available to
stop the bleeding in the field in complex situations.
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